Case Study: a pre-revenue biotech company achieves higher valuation clarity with Evaluate forecasting and valuation

Analysis of Lead Asset Sales Potential for a Pre-Revenue Biotech Executive Team

Evaluate helped a pre-revenue biotech company determine which lead indication for its primary asset would drive the highest company valuation ahead of a key milestone. The client needed an objective analysis to inform this critical strategic decision.

The Evaluate solution involved creating scenario-based forecast and revenue models for eight different indications, incorporating treatment paradigm positioning and expert insights. This provided the client with an external viewpoint that challenged internal perceptions; the findings were presented to the Board and incorporated into the company's ongoing strategic planning.